Cancer Vaccines Market

Market Overview:

The global cancer vaccines market reached a value of US$ 5.43 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 10.72 Billion by 2027, exhibiting a CAGR of 11.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor. 

Cancer is a malignant tumor caused by the uncontrollable growth of abnormal cells in the body. It can be treated through the use of various medications and vaccines. Between these, vaccines are broadly categorized into preventive and therapeutic. Preventive cancer vaccines are deployed for eliminating cancer caused by oncovirus and protecting from human papillomavirus (HPV), whereas therapeutic vaccines aid in stimulating the individual adaptive immune systems by using tumor antigens. At present, cancer vaccines are commercially available in varying types, such as antigen, dendritic cell, and anti-idiotype. 

Cancer Vaccines Market Trends:

The increasing prevalence of cancer, especially due to the rising consumption of tobacco-based products and evolving lifestyles is currently driving the cancer vaccines market growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel cancer vaccines, along with extensive fundings in the field of viral recombinant cancer vaccines are further facilitating the widespread adoption of these vaccines in the healthcare sector. In line with this, the extensive utilization of United States Food and Drug Administration (US FDA) approved vaccines, including human papillomavirus vaccine (HPV) and hepatitis B vaccine (HBV) to reduce the risk of certain types of cancer, such as liver cancer, is contributing to the market growth. The market is also significantly driven by rapid technological advancements focusing on the development of effective and specific cancer treatments. Other factors, such as improving healthcare infrastructure, rising geriatric population, who are susceptible to various chronic ailments, including cancer, and growing consumer awareness regarding the symptoms and the available treatment options, are creating a positive outlook for the market further across the globe.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer vaccines market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, technology, indication and end user.

Breakup by Type:

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
   

Breakup by Technology:

• Dendritic Cells Cancer Vaccines
• Recombinant Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Viral Vector and DNA Cancer Vaccines
• Whole-cell Cancer Vaccines
   

Breakup by Indication:

• Cervical Cancer
• Prostate Cancer
• Others
   

Breakup by End User:

• Pediatrics
• Adults
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.

Report Coverage:

Key Questions Answered in This Report:

• How has the global cancer vaccines market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global cancer vaccines market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global cancer vaccines market and who are the key players?
• What is the degree of competition in the industry?